

Date of the CVA	05/03/2019
-----------------	------------

## Section A. PERSONAL DATA

Name and Surname	Alberto Ortiz Arduan		
DNI	00803587j	Age	55
Researcher's identification number	Researcher ID	Y-7582-2018	
	Scopus Author ID		
	ORCID	0000-0002-9805-9523	

### A.1. Current professional situation

Institution	Instituto de Investigación Sanitaria Fundación Jiménez Díaz		
Dpt. / Centre			
Address	Fundacion Jimenez Diaz, Av Reyes Catolicos 2, 28040, Madrid		
Phone	655538941	Email	<a href="mailto:aortiz@fjd.es">aortiz@fjd.es</a>
Professional category	Jefe de servicio	Start date	2010
UNESCO spec. code	320000 - Medical Science		
Keywords			

### A.2. Academic education (Degrees, institutions, dates)

Bachelor/Master/PhD	University	Year
Programa Oficial de Doctorado en Medicina	Universidad Autónoma de Madrid	1992
Licenciado en Medicina y Cirugía	Universidad Autónoma de Madrid	1987

### A.3. General quality indicators of scientific production

>550 publications peer-reviewed journals in English. ·h-index: 66 (WOS)/81 (Google Scholar-GS 1IKOVx0AAAAJ, i10 index 371). Citations: 23836 WOS/ 29308 GS. 6841 WOS citations January-December 2018. 6 patents. 24 PhD thesis. Accumulated impact factor, >4370. High impact publications: Lancet (25), Lancet Diabetes Endocrinol (4), PNAS USA (3), JASN (24), Kidney Int (35), Nat Rev Nephrol (6) Diabetes (2) and others.

According to the Expetscape website ([expertscape.com/](http://expertscape.com/)), based on the publications record of the past 10 years, AO is ranked #1 in Spain and #12 in Europe in the topic Kidney diseases.

For the period 2014-2018, >257 publications, 79 D1, and additional 71 Q1 (not D1). h-index: 32 (WOS)/57 (GS i10 index 283). Citations: 18270 WOS/ 21105 GS. 6 patents. 12 PhD thesis. Accumulated impact factor, >2479. High impact publications: Lancet (25), Lancet Diabetes Endocrinol (4), PNAS USA (2), JASN (6), Kidney Int (5), Nat Rev Nephrol (4), Diabetes Care (1), Trends Molec Med (1) and others.

## Section B. SUMMARY OF THE CURRICULUM

Prof Alberto Ortiz, MD, PhD, Chief of Nephrology and Hypertension at Health Research Institute of the Jiménez Díaz Foundation (IIS-FJD); Professor of Medicine at Autonomous University of Madrid (UAM); Councilor at Spanish Society of Nephrology (SEN) and European Renal Best Practice (ERBP, the clinical guidelines body at ERA-EDTA) member; core member of European Uremic Toxins (EUTox) and of the Fabry Registry European Board, coordinates the Spanish Renal Research Network (RETIC REDINREN, from 2013) and the ITEMAS innovation platform node at IIS-FJD, Editor-in-Chief for Clinical Kidney Journal which in 2019 receives its first IF estimated to be around 3.0, editorial board member for J Nephrol and Nefrologia, among others, Scientific Program Director for the 2019 ERA-EDTA Congress. Prof. Ortiz studied Medicine at the UAM, specialized in Nephrology at the IIS-FJD, post-doctoral research fellow at the U. Pennsylvania, PA, USA (1992–1994) before returning to the IIS-FJD as Senior Researcher and later as Staff Nephrologist. A physician-scientist: his research career started in 1985 as a 5th year medical student awarded a basic research CSIC grant, and was a full time basic researcher for 5 years (2 in USA and 3 in Spain). Research interests: pathogenesis and treatment of kidney disease and vascular injury in kidney disease. From 2006 to 2017 he was a recipient of a Research Activity Intensification grant

of the ISCIII. He has been principal investigator for 9 Spain National Research Plan projects, including non-commercial clinical trials, a EU research project (PRIORITY), 4 Community of Madrid research projects and 3 nationwide research networks, including REDINREN. Has been director/mentor of 11 public competitive research contracts: 4 post-specialty research contracts for nephrologists (Rio Hortega), 3 Sara Borrell early-stage post-doctoral contract, 3 Miguel Servet senior post-doctoral contracts and 2 physician-scientist Joan Rodes contract. He directed multiple PhD grantees funded by private and public competitive sources, resulting in 25 successfully defended PhD dissertations and 9 ongoing PhD theses. He was Secretary of the European REnal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association (ERA-EDTA), Scientific Advisory Board (SAB) ERA-EDTA member, Vice-dean for research at the School of Medicine UAM, editorial board member for J Am Soc Nephrol (the top nephrology journal), Spanish representative in the European Cost Action EUROKUP, international coordinator for the gevokizumab phase II RCT in diabetic nephropathy and EMA expert on nephrotoxicity biomarkers, contributor to ERBP clinical guidelines on Fabry and autosomal dominant polycystic kidney disease (ADPKD) and to Spanish guidelines on ADPKD and advanced CKD management, associate editor at NDT 2015-2017 and Councilor ERA-EDTA 2015-2017. Participated in KDIGO Conferences on Fabry disease and Rare Diseases. Invited to write reviews/editorial comments to Lancet, Lancet Endocrinology, JASN, Kidney Int, J Pathol, NDT and others. Reviewer for >60 journals, including NEJM, Lancet and for National funding bodies in 10 European countries. 6 patent and 1 patent applications.

## Section C. MOST RELEVANT MERITS (ordered by typology)

### C.1. Publications

- 1 **Scientific paper.** Ortiz, A.; et al. 2017. Mitogen-Activated Protein Kinase 14 Promotes AKI. J Am Soc Nephrol. 28-3, pp.823-836.
- 2 **Scientific paper.** Fernandez Fernandez, B.; et al. 2018. Albumin downregulates Klotho in tubular cells. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 33-10, pp.1712-1722. ISSN 1460-2385.
- 3 **Scientific paper.** González Guerrero, C.; et al. (11/10). 2018. CCL20 blockade increases the severity of nephrotoxic folic acid-induced acute kidney injury. The Journal of pathology. 246-2, pp.191-204. ISSN 1096-9896.
- 4 **Scientific paper.** Navarro González, JF.; et al. (10/9). 2018. Effects of Pentoxifylline on Soluble Klotho Concentrations and Renal Tubular Cell Expression in Diabetic Kidney Disease. Diabetes care. 41-8, pp.1817-1820. ISSN 1935-5548.
- 5 **Scientific paper.** D 4. Martin-Sanchez; et al. (11/10). 2018. TWEAK and RIPK1 mediate a second wave of cell death during AKI Proc Natl Acad Sci U S A. 115, pp.4187-4187.
- 6 **Scientific paper.** Rubio Navarro, A.; et al. (19/17). 2018. Podocytes are new cellular targets of haemoglobin-mediated renal damage. The Journal of pathology. 244-3, pp.296-310. ISSN 1096-9896.
- 7 **Scientific paper.** González Guerrero, C.; et al. (6/5). 2017. TLR4-mediated inflammation is a key pathogenic event leading to kidney damage and fibrosis in cyclosporine nephrotoxicity. Archives of toxicology. 91-4, pp.1925-1939. ISSN 1432-0738.
- 8 **Scientific paper.** Suarez Alvarez, B.; et al. 2017. Inhibition of Bromodomain and Extraterminal Domain Family Proteins Ameliorates Experimental Renal Damage. Journal of the American Society of Nephrology : JASN. 28-2, pp.504-519. ISSN 1533-3450.
- 9 **Scientific paper.** Martin Sanchez, D.; et al. (11/10). 2017. Ferroptosis, but Not Necroptosis, Is Important in Nephrotoxic Folic Acid-Induced AKI. Journal of the American Society of Nephrology : JASN. 28-1, pp.218-229. ISSN 1533-3450.
- 10 **Scientific paper.** Poveda J; et al. (7/7). 2017. Bcl3: a regulator of NF- $\kappa$ B inducible by TWEAK in acute kidney injury with anti-inflammatory and antiapoptotic properties in tubular cells Exp Mol Med. 49-7, pp.e352.
- 11 **Scientific paper.** Ruiz Andres, O.; et al. (9/8). 2016. The inflammatory cytokine TWEAK decreases PGC-1 $\alpha$  expression and mitochondrial function in acute kidney injury. Kidney international. 89-2, pp.399-410. ISSN 1523-1755.

- 12 **Scientific paper.** Ruiz-Andres O; et al. 2016. Histone lysine crotonylation during acute kidney injury in mice *Dis Model Mech.* 9-6, pp.633-45.
- 13 Eren, OC.; et al. 2019. Multilayered Interplay Between Fructose and Salt in Development of Hypertension. *Hypertension (Dallas, Tex. : 1979).* 73-2, pp.265-272. ISSN 1524-4563.
- 14 Fernandez Fernandez, B.; Sanchez Niño, MD.; Ortiz, A.2019. Working towards novel albuminuria endpoints in chronic kidney disease. *The lancet. Diabetes & endocrinology.* 7-2, pp.80-82. ISSN 2213-8595.
- 15 Perez Gomez, MV.; et al. (6/6). 2019. Potential Dangers of Serum Urate-Lowering Therapy. *The American journal of medicine.* ISSN 1555-7162.
- 16 Ferro, CJ.; et al. 2018. Lipid management in patients with chronic kidney disease. *Nature reviews. Nephrology.* 14-12, pp.727-749. ISSN 1759-507X.
- 17 Fernandez Fernandez, B.; Ortiz, A.2018. Paricalcitol and albuminuria: tread carefully. *The lancet. Diabetes & endocrinology.* 6-1, pp.3-5. ISSN 2213-8595.
- 18 Zheng-Lin B; Ortiz A. 2018. Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting Drugs. 78-2, pp.215-229.
- 19 Ortiz, A.; et al. 2014. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. *Lancet (London, England).* 383-9931, pp.1831-1843. ISSN 1474-547X.

## C.2. Participation in R&D and Innovation projects

- 1 ERAPERMED Kidney Attack International coordinator (ERA PerMed). 01/01/2019-31/12/2021. 895.319 €. Principal investigator.
- 2 CIFRA consorcio de investigacion de la comunidad autonoma de madrid alberto ortiz arduan. (IIS fundacion Jimenez diaz). 01/01/2018-31/12/2021. 100.000 €.
- 3 RD16/0009/0001. Coordinador de la Red Nacional de Investigación en Enfermedades renales (RETIC REDINREN) del Fondo de Investigación Sanitaria 2017-2021 (IIS-FJD). 01/01/2017-31/12/2021. 3.345.000 €.
- 4 Renal MRI. Magnetic Resonance Imaging Biomarkers for Chronic Kidney Disease (European Cooperation in Science & Technology (COST)). 01/04/2017-01/04/2021. 135.000 €.
- 5 IP Plataforma de Innovación en Tecnologías Médicas y Sanitarias (ITEMAS) PT17/0005/0016) 2018-2021.
- 6 Reposicionamiento de nuevas formulaciones de 3,7-Dimethyl-1-(5-oxohexyl)-3,7-dihydro-1Hpurine-2,6-diona para retrasar el envejecimiento. PI, DTS18/00032 ISCIII (Fundación Jiménez Díaz). 01/01/2019-31/12/2020. 99.550 €.
- 7 tutor Sara borrell Julio Manuel Martínez Moreno (IIS FJD UAM). 01/01/2018-31/12/2020.
- 8 Tutor de Miguel Servet-Maria Dolores Sanchez-Niño Instituto de Salud Carlos III. (IIS-FJD). 14/01/2015-13/01/2020.
- 9 PersTIgAN Personalized Treatment in IgA Nephropathy (ERA PerMed). 2019-2020. 88.330 €.
- 10 MARIE CURIE ACTIONS. Innovative Training Networks (ITN). CaReSyAn. Combatting the CardioRenal Syndrome: towards an integrative Analysis to reduce cardiovascular burden in chronic kidney disease 2017-2020. Team member.
- 11 Open Multiscale Systems Medicine (OpenMultiMed) (European Cooperation in Science & Technology (COST)). 2015-2020. Team member.
- 12 IP FIS PI16/02057, ISCIII. Caracterización de nuevos factores nefroprotectores y aplicaciones terapéuticas (IIS-FJD). 01/01/2017-31/12/2019. 304.315 €.
- 13 Tutor de P-FIS Lara Valiño Instituto de Salud Carlos III. Lara Valiño. (IIS-FJD). 2015-2018. Co-ordinator.
- 14 JR14/00028, Tutor de Juan Rodés Beatriz Fernández-Fernández Instituto de Salud Carlos III. Juan Rodés. (IIS-FJD). 01/01/2015-31/12/2017. Co-ordinator.
- 15 IP Proyecto union europea PRIORITY: Proteomic prediction and Raas inhibition prevention of early diabetic nephropathy in type 2 diabetic patients with normoalbuminuria (FP7-HEALTH.2011.2.4.3-1) Ortiz A. (IIS-Fundacion Jimenez Diaz). 01/01/2012-31/12/2017. 6.000.000 €.
- 16 IP PT13/0006/0006 Plataforma ITEMAS (IIS-FJD). 01/2013-12/2017.

- 17 Coordinador RedinREN 12/0021 (RETICS 2012) Instituto de Salud Carlos III. ortiz a. (IIS-FJD). 2013-2017. 798.675 €. Co-ordinator.
- 18 IP RedinREN 12/0021/001 (RETICS 2012) Instituto de Salud Carlos III. Alberto Ortiz Arduán. (IIS-FJD). 2013-2017. 120.750 €. Co-ordinator.
- 19 IP DiabetesCancerConnect:Targeting common inflammatory markers and signaling pathways in diabetes mellitus and cancer Jesus Egido. (IIS-FJD). 01/01/2014-31/12/2016. 800.000 €.
- 20 IP Implicaciones terapéuticas de nuevos mediadores del daño renal identificados mediante transcriptómica y proteómica Instituto de Salud Carlos III. alberto ortiz arduan. (IIS-FJD). 01/01/2014-31/12/2016. 171.000 €.
- 21 FP7-PEOPLE-2013-ITN – 608332, iMODE-CKD ITN (Clinical and system –omics for the identification of the MOlecular DEterminants of established Chronic Kidney Disease) Union Europea. Alberto Ortiz. (IIS-FJD). 01/01/2013-31/12/2016.
- 22 Tutor de Miguel Servet 2-Adrian Mario Ramos Instituto de Salud Carlos III. (IIS-FJD). 27/12/2015-27/12/2016.
- 23 Tutor de Sara Borrell Maria Encarnacion Rodriguez Ortiz Instituto de Salud Carlos III. Sara Borrell. (IIS-FJD). 2014-2016. Co-ordinator.
- 24 Coordinador IBERERC (Iberoamérica enfermedad renal crónica) Programa Iberoamericano de Ciencia y Tecnología para el Desarrollo. Alberto Ortiz. 2013-2016. Co-ordinator.
- 25 Tutor European Renal Association ERA-EDTA Research fellowship program European Renal Association ERA-EDTA. Lucie Henaut. 2014-2015. Co-ordinator.
- 26 Rio Hortega Laura Rodríguez-Osorio Instituto de Salud Carlos III. Río Hortega. Laura Rodríguez-Osorio. (IIS-FJD). 2013-2014. Co-ordinator.
- 27 Identificación por transcriptómica de mediadores moleculares de la fibrosis en la enfermedad de Fabry Fundación Genzyme en Enfermedades de depósito Lisosomal. Alberto Ortiz. (IIS-FJD). From 2013.

### C.3. Participation in R&D and Innovation contracts

Interaction of diabetes and fabry disease, scientific coordinator Sanofi Genzyme. alberto ortiz arduan. 01/01/2018-01/01/2021. 200.000 €.

### C.4. Patents

- 1 A Ortiz; J; AB Sanz; MD Sánchez Niño. P201631183. Elaboración de un medicamento para prevenir el envejecimiento prematuro en humanos, composición farmacéutica y uso de la sobreexpresión de Bcl3 Spain. 12/09/2016. FIIS-FJD.
- 2 Alberto Ortiz; MD Sánchez Niño; AB Sanz; J Poveda. P201531933. Elaboración de un medicamento para prevenir el envejecimiento prematuro en humanos, composición farmacéutica y método de selección de compuestos basado en el uso de siRNA de NFKbiz Spain. 30/12/2015. FIIS-FJD.
- 3 Alberto Ortiz; MD Sánchez Niño; AB Sanz; O Ruiz-Andrés. P201531677. Derivados del Crotonato para la fabricación de un medicamento para el tratamiento de la enfermedad renal crónica y fracaso renal agudo Spain. 19/11/2015. FIIS-FJD.
- 4 Alberto Ortiz; MD Sánchez Niño; M Fresno. P201531328. Papel de MAP3K14 en la prevención y tratamiento del fallo renal agudo Spain. 18/09/2015. FIIS-FJD.
- 5 Alberto Ortiz; MD Sánchez Niño; AB Sanz; JF Navarro González. P201530616. Pentoxifilina para conservar o aumentar la expresión del gen anti envejecimiento Klotho Spain. 06/05/2015. FIIS-FJD, HU Ntra Sra. De Candelaria.
- 6 Alberto Ortiz; MD Sanchez Niño. 201430081. Composición farmacéutica y su uso para la fabricación de un medicamento para el tratamiento de la enfermedad renal crónica y método de selección de compuestos Spain. 27/01/2014. FIIS\_FJD FIB HU La Paz.